Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Vestal Point Capital, LP
Form 13F · Q2 2026

Vestal Point Capital, LP

CIK 1974915Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$4.3B
Reported book value
68
Positions
11
Quarters on record
Top 50
Positions

Vestal Point Capital, LP — holdings

Top 50 positions of 68, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1BMRN Biomarin Pharmaceutical Inc6.0M+68.5%$345M8.1%
2NBIX Neurocrine Biosciences Inc1.9M+50.4%$317M7.4%
3ABIVAX SA Abivax Sa2.3M+56.6%$313M7.3%
4UTHR United Therapeutics Corp Del435,000+480.0%$236M5.5%
5ELVN Enliven Therapeutics Inc4.0M+23.1%$203M4.7%
6NRIX Nurix Therapeutics Inc8.1M+23.8%$195M4.6%
7BCAX Bicara Therapeutics Inc5.2M−3.2%$156M3.6%
8TSHA Taysha Gene Therapies Inc19.4M+7.9%$132M3.1%
9ARWR Arrowhead Pharmaceuticals In1.6M−30.8%$128M3.0%
10ABT Abbott Laboratories1.4M—$127M3.0%
11ZBH Zimmer Biomet Holdings Inc1.4M+636.8%$121M2.8%
12IRON Disc Medicine Inc1.6M+121.4%$113M2.6%
13GLUE Monte Rosa Therapeutics Inc4.6M+27.7%$111M2.6%
14PODD Insulet Corp670,000+1224.1%$102M2.4%
15ASND Ascendis Pharma A/S375,000—$100M2.3%
16AZN Astrazeneca Plc450,000+350.0%$85M2.0%
17SNY Sanofi Sa2.0M+42.9%$85M2.0%
18RVMD Revolution Medicines Inc450,000−81.1%$84M2.0%
19BCRX Biocryst Pharmaceuticals Inc8.3M+18.1%$83M1.9%
20DYN Dyne Therapeutics Inc3.4M−15.6%$75M1.8%
21NKTR Nektar Therapeutics1.0M+250.9%$70M1.6%
22GMED Globus Med Inc850,000+39.2%$67M1.6%
23TARS Tarsus Pharmaceuticals Inc1.1M+425.0%$66M1.5%
24IMTX Immatics N.V6.2M+0.0%$63M1.5%
25TRVI Trevi Therapeutics Inc3.1M+43.1%$58M1.4%
26IMCR Immunocore Hldgs Plc1.8M−34.9%$57M1.3%
27RGEN Repligen Corp400,000−56.8%$55M1.3%
28BMY Bristol-Myers Squibb Co800,000−20.0%$46M1.1%
29UNIQURE NV Uniqure Nv935,000+160.4%$43M1.0%
30XENE Xenon Pharmaceuticals Inc700,000+9.4%$42M1.0%
31DRUG Bright Minds Biosciences Inc545,000+10.7%$38M0.9%
32MDGL Madrigal Pharmaceuticals Inc65,000+106.6%$35M0.8%
33ALC Alcon Ag500,000−37.5%$34M0.8%
34MYGN Myriad Genetics Inc5.7M+248.0%$33M0.8%
35RAPP Rapport Therapeutics Inc730,000−49.2%$30M0.7%
36CBIO Crescent Biopharma Inc.1.6M+8.7%$29M0.7%
37GEHC Ge Healthcare Technologies I450,000+80.0%$29M0.7%
38INSM Insmed Inc250,000—$27M0.6%
39VKTX Viking Therapeutics Inc680,000−25.6%$27M0.6%
40BBNX Beta Bionics Inc1.6M−27.7%$25M0.6%
41REGN Regeneron Pharmaceuticals40,000+0.0%$25M0.6%
42SLDB Solid Biosciences Inc2.2M−56.8%$22M0.5%
43ANRO Alto Neuroscience Inc785,000−62.0%$21M0.5%
44TRAX First Tracks Biotherapeutics1.0M—$20M0.5%
45LXEO Lexeo Therapeutics Inc4.3M−3.5%$20M0.5%
46SVRA Savara Inc2.7M+4.6%$17M0.4%
47DMRA Damora Therapeutics Inc575,000−4.2%$15M0.3%
48SGP Spyglass Pharma Inc670,000+0.5%$15M0.3%
49TECX Tectonic Therapeutic Inc425,000+29.6%$15M0.3%
50AVTX Avalo Therapeutics Inc775,000—$14M0.3%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.